Unicycive Therapeutics, Inc. (UNCY)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.73
- As of
Kresmion compiles this page from UNCY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Unicycive Therapeutics, Inc. (UNCY): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
See the full UNCY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for UNCY on one page. Preview it with sample data, then open it live with a free account.
Preview the UNCY dossierActive signals for UNCY
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 82.5%, EPS $-0.06 vs $-0.343 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1255% to UNCY (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +461% to UNCY (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +749% to UNCY (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 81% of UNCY (2026Q2)
FREE, NO ACCOUNT
Every signal on UNCY, as it fires
You are seeing 5 of 10 signals recorded on UNCY since 2026-05-30.
The five above landed across 2 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in UNCY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 90466Y202 · 2026Q2 | $1.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 90466Y202 · 2026Q2 | $287K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, UNCY
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
UNCY against its peers
UNCY's return on equity of -87.9% ranks in the 69th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2025-12-31.
| Metric | UNCY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 7.9M | n/a | 13 |
| Operating margin | n/a | -281.7% | n/a | 10 |
| Net margin | n/a | -253.7% | n/a | 10 |
| Return on equity | -87.9% | -105.9% | 69 | 17 |
| 1 year | -16.9% | -38.3% | 82 | 18 |
Peers (21): ANIX, HUMA, MIST, GNLX, BDTX, PYPD, LENZ, ATRA, RANI, FHTX, PLYX, CLLS, VANI, BMEA, SPRB, VXRT, HURA, SMNR, COYA, OKUR, IMUX. Left out: SPRC (period gap), CNXU (no annual filing), HSTC (period gap), TNXP (no annual filing). Fiscal periods ending between 2025-10-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (UNCY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow UNCY on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to UNCY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.